Skip to main content
SpringerLink
Log in

A sensitive chemiluminescent immunoassay for point-of-care testing of repaglinide in natural dietary supplements and serum

  • Research Paper
  • Published:
Analytical and Bioanalytical Chemistry Aims and scope Submit manuscript

Abstract

For point-of-care testing of the illegal fortification of repaglinide (Rep) in natural dietary supplements, a competitive chemiluminescent immunoassay (CLIA) was established, using a horseradish peroxidase (HRP)–luminol–H2O2 system for signal amplification. Polyclonal antibodies for Rep were produced via immunization technique. Following optimization of the enzyme reaction time and concentrations of antibody and coating antigen, the method showed a limit of quantification (LOQ) of 1.0 ng/mL in PBS and limit of detection (LOD) of 8.3 ng/mL in serum and 6.0 ng/mL in blank tablets. When applied in natural dietary supplements, the method provided results consistent with those from HPLC, suggesting that the proposed method could be used for rapid screening of Rep in natural dietary supplements and detecting Rep in serum after administration.

A sensitive chemiluminescent immunoassay for rapid analysis of repaglinide in natural dietarysupplements and serum

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Owens DR (1998) Repaglinide–prandial glucose regulator: a new class of oral antidiabetic drugs. Diabet Med 15:S28–S36. doi:10.1002/(SICI)1096-9136(1998120)

    Article  Google Scholar 

  2. Bech P, Moses R, Gomis R (2003) The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy-naive type 2 diabetes: a placebo-controlled, multicentre study. Qual Life Res 12:413–425. doi:10.1023/A:1023495106160

    Article  Google Scholar 

  3. Hasslacher C (2003) Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 26:886–891. doi:10.2337/diacare.26.3.886

    Article  CAS  Google Scholar 

  4. Hatorp V, Huang WC, Strange P (1999) Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes. J Clin Endocrinol Metab 84:1475–1478. doi:10.1210/jc.84.4.1475

    Article  CAS  Google Scholar 

  5. Gumieniczek A, Berecka A, Hopkala H (2005) Quantitative analysis of repaglinide in tablets by reversed-phase thin-layer chromatography with densitometric UV detection. J Planar Chromatogr Mod TLC 18:155–159. doi:10.1556/JPC.18.2005.2.12

    Article  CAS  Google Scholar 

  6. Gandhimathi M, Ravi TK, Renu SK (2003) Determination of repaglinide in pharmaceutical formulations by HPLC with UV detection. Anal Sci 19:1675–1677. doi:10.2116/analsci.19.1675

    Article  CAS  Google Scholar 

  7. Soni LK, Narsinghani T, Jain M (2012) Development and validation of RP-HPLC method for simultaneous estimation of metformin hydrochloride and repaglinide in tablet dosage form. J Liq Chromatogr Relat Technol 35:385–392. doi:10.1080/10826076.2011.601492

    Article  CAS  Google Scholar 

  8. Ho EN, Yiu KC, Wan TS, Stewart BD, Watkins KL (2004) Detection of anti-diabetics in equine plasma and urine by liquid chromatography–tandem mass spectrometry. J Chromatogr B 811:65–73. doi:10.1016/j.jchromb.2004.03.070

    Article  CAS  Google Scholar 

  9. Zhang J, Gao F, Guan X, Sun YT, Gu JK, Fawcett JP (2011) Determination of repaglinide in human plasma by high-performance liquid chromatography–tandem mass spectrometry. Acta Pharm Sin B 1:40–45. doi:10.1016/j.apsb.2011.04.004

    Article  CAS  Google Scholar 

  10. Jiladia MA, Pandya SS (2009) Estimation of repaglinide in bulk and tablet dosage forms by HPTLC method. Int J Pharm Pharm Sci 1(Supp 1):141–144

    CAS  Google Scholar 

  11. De Boever J, Kohen F, Usanachitt C, Vandekerckhove D, Leyseele D, Vandewalle L (1986) Direct chemiluminescence immunoassay for estradiol in serum. Clin Chem 32:1895–1900

    Google Scholar 

  12. Dodeigne C, Thunus L, Lejeune R (2000) Chemiluminescence as diagnostic tool. A review. Talanta 51:415–439. doi:10.1016/S0039-9140(99)00294-5

    Article  CAS  Google Scholar 

  13. Maters AW, Wright CV, Lee MT, Schwichtenberg G, Detrick B (2012) Detection of type-specific antibodies to HSV-1 and HSV-2: comparative analysis of a chemiluminescence immunoassay with a conventional ELISA. Diagn Microbiol Infect Dis 73:273–274. doi:10.1016/j.diagmicrobio.2012.03.023

    Article  CAS  Google Scholar 

  14. Zhang Y, Lu S, Liu W, Zhao C, Xi R (2007) Preparation of anti-tetracycline antibodies and development of an indirect heterologous competitive enzyme-linked immunosorbent assay to detect residues of tetracycline in milk. J Agric Food Chem 55:211–218. doi:10.1021/jf062627s

    Article  CAS  Google Scholar 

  15. Hermanson GT (2013) Vaccines and immunogen conjugates. Bioconjugate techniques, 3rd edn, vol 19. Pierce Biotechnology/Thermo Fisher Scientific, Rockford, pp 839–865. doi:10.1016/B978-0-12-382239-0.00019-4

    Google Scholar 

  16. Xin TB, Chen H, Lin Z, Liang SX, Lin JM (2010) A secondary antibody format chemiluminescence immunoassay for the determination of estradiol in human serum. Talanta 82:1472–1477. doi:10.1016/j.talanta.2010.07.023

    Article  CAS  Google Scholar 

  17. Qin QP, Peltola O, Pettersson K (2003) Time-resolved fluorescence resonance energy transfer assay for point-of-care testing of urinary albumin. Clin Chem 49:1105–1113. doi:10.1373/49.7.1105

    Article  CAS  Google Scholar 

Download references

Acknowledgment

This work was received financial support from the National Natural Science Foundation (No. 81173017, No. 31101277), the National High-Tech Research and Development Program of China (863 Program) (No. 2014AA022303), Tianjin Science and Technology Program (No. 11ZCGHHZ01200, No. 12ZXCXSY08400, No. 12JCQNJC08900), and Tianjin Research Program of Application Foundation and Advanced Technology (13JCZDJC29700).

Author information

Author notes

    Authors and Affiliations

    1. College of Pharmacy, State Key Laboratory of Medicinal Chemical Biology and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, 300071, China

      Lei Zheng, Jing Wang, Yufen Wang, Zhaorui Song, Yaqing Dong, Yongmei Yin, Meng Meng & Rimo Xi

    2. Faculty of Chemistry, M.V. Lomonosov Moscow State University, Moscow, 119991, Russia

      Sergei A. Eremin

    Authors
    1. Lei Zheng
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Jing Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Yufen Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Zhaorui Song
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Yaqing Dong
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Yongmei Yin
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Sergei A. Eremin
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Meng Meng
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Rimo Xi
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Meng Meng or Rimo Xi.

    Additional information

    Lei Zheng and Jing Wang contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Zheng, L., Wang, J., Wang, Y. et al. A sensitive chemiluminescent immunoassay for point-of-care testing of repaglinide in natural dietary supplements and serum. Anal Bioanal Chem 407, 1973–1980 (2015). https://doi.org/10.1007/s00216-015-8462-3

    Download citation

    • Received:

    • Revised:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00216-015-8462-3

    Keywords

    Search

    Navigation